Eevia Health

Ticker/ISIN

EEVIA

FI4000496658

Marknad/Land

Spotlight

Sweden

Om Eevia Health

Eevia Health är verksamt inom life science. Bolaget erbjuder produktionsprotokoll och procedurer för att leverera ekologiska produkter till internationella kunder. Produkterna säljs till företagskunder och inkluderar ingredienser till producenter av kosttillskott, livsmedel och kosmetika på global basis. Produkterna innefattar exempelvis blåbär, chaga-svamp och tallbark. Eevia Health grundades 2017 och har sitt huvudkontor i Seinäjoki, Finland.

Senaste sammanfattade pressmeddelande från Eevia Health

Terry Virts resigned from the Board to pursue a political career, with his departure to be addressed at an Extraordinary General Meeting (EGM) on May 30. However, due to absences, the EGM was not legally convened, leaving the vacancy unfilled. The Annual General Meeting (AGM) was also delayed, extending the issue over the summer. The resignation was registered on July 2, but a clerical error misidentified the Chairman. In January 2025, Marinus Sørensen was appointed to fill a vacancy, but questions arose about the legality of the appointment, which was not registered with the Finnish Patent and Registration Office (PRH). Eevia is addressing these issues by updating registrations and planning elections at the upcoming General Meeting. Eevia Health Plc is a company that produces sustainable bioactive extracts from Nordic plants for global nutraceutical brands, focusing on health benefits. It operates in Finland and is listed on the Spotlight Stock Market in Sweden. For more information, contact Stein Ulve, CEO of Eevia Health Plc.

Press release from Companies: Changes to the Eevia Board

för 4 dagar sedan

Eevia Health Plc continues to face liquidity challenges, lacking access to new non-dilutive funding and unable to conduct equity issues. Despite these challenges, the company's restructuring plan is progressing, with slight revenue growth and new sales contracts that could support future growth. Eevia is also exploring sales opportunities with major global companies. Recent sales from inventory have generated cash, and significant cost reductions were made over the summer. Plans to relocate production to a new facility are underway, which could reduce future operational expenses. However, the company faces short debt maturities and insufficient cash flow to cover obligations. Creditors are demanding payments, and there is pressure to finalize repayment plans for statutory debts. The company's financial position has led to an evaluation of its going concern status and asset liquidation value, delaying the audit process and 2024 financial statements. Significant write-downs on assets have been agreed upon, affecting reported equity as of December 31, 2024, but these adjustments aim to secure an unqualified audit opinion. The audit report is expected by August 20, and a General Meeting will be called upon its receipt. Eevia Health specializes in sustainable bioactive extracts from Nordic plants and berries, focusing on gut, kidney, urinary health, cellular protection, and inflammation. Founded in 2017, it produces organic plant extracts, primarily from Finnish and Swedish forests, sold to global nutraceutical brands. Eevia is listed on the Spotlight Stock Market in Sweden under the ticker EEVIA.

Press release from Companies: UPDATE: Eevia Warns of Continued Strained Liquidity, Delayed Audit and Write Downs

för 4 dagar sedan

Eevia Health Plc has announced new sales orders totaling EUR 49,800 for its organic bioactive ingredients, including elderberry, pine bark, bilberry, and tart cherry extracts. These sales occur during a challenging period for the company but positively impact short-term liquidity and demonstrate ongoing customer demand. All products are available from inventory, ensuring immediate delivery and supporting cash flow improvements. CEO Stein Ulve highlighted the orders as evidence of the company's strong product portfolio and market trust, which align with Eevia's plans to restructure operations and relocate production to more supportive regions. Eevia Health, founded in 2017, focuses on sustainably extracted bioactive compounds for global health challenges and operates a modern production facility in Finland. The company is listed on the Spotlight Stock Market in Sweden.

Press release from Companies: Eevia Health Secures c. EUR 50,000 in New Sales Orders Across Key Markets

för 2 månader sedan

Eevia Health has received HALAL certification from HQC, confirming that its production processes and select product lines meet international HALAL standards. This certification allows Eevia to expand into markets where HALAL compliance is essential, such as parts of the Middle East, Southeast Asia, and North Africa, as well as among HALAL-conscious consumers in Europe and North America. Eevia's core range of organic extracts, including elderberry and bilberry, are now HALAL-compliant, aligning with global demand for certified natural health ingredients. The certification supports Eevia's commitment to quality and market growth, as the company restructures to better serve strategic markets. Eevia Health, founded in 2017, produces organic plant extracts from Finnish and Swedish forests, focusing on gut and related health. It operates a green-chemistry facility in Finland and is listed on the Spotlight Stock Market in Sweden. For more information, contact Stein Ulve, CEO, or visit their website.

Press release from Companies: Eevia Health Receives HALAL Certification, Unlocking New Market Opportunities

för 2 månader sedan

Eevia Health has been repositioning for global growth after losing a significant portion of its revenue from a major U.S. customer in 2023. The company is now working with several global nutraceutical brands and focusing on polyphenol-rich botanical extracts from Arctic plants. Eevia plans to close its manufacturing site in Finland due to a lack of public and non-dilutive funding and move production to BIOTEP in Tromsø, Norway, which offers advanced facilities and reduced costs. This move will impact up to eight employees in Finland, but Eevia will maintain its core functions in sales, R&D, and market development. The partnership with Nofima and BIOTEP will allow Eevia to optimize production and innovate without major upfront investments. Eevia aims to improve profitability and sustainability by converting side-stream materials into sellable products. The company is focused on restoring profitability and cash flow through strategic moves and partnerships. Eevia Health specializes in sustainable bioactive extracts from Nordic plants and berries, offering ingredients for gut health, cellular protection, and inflammation, and operates a modern production facility in Finland.

Press release from Companies: Eevia Health Relocates Production to Norwegian Nutraceutical Biotechnology Hub to Drive Innovation, Avoid Investments and Cut Costs

för 2 månader sedan

Eevia Health Plc, a company specializing in sustainable bioactive extracts, is facing ongoing liquidity challenges. Despite reducing operating costs and recovering some revenue after losing a major customer in July 2023, the company continues to struggle financially, operating with negative EBITDA. Eevia has conducted two rights issues, raising nearly €2 million in equity, but has been unable to secure non-dilutive funding from Finnish institutions, with several funding applications rejected. The management has been working on a turnaround plan involving new sales contracts and cost optimization, but the lack of financial backing has led to some investors withdrawing support. Eevia plans to shift R&D and production to more supportive regions to address funding gaps. The company is implementing an urgent plan to generate cash by selling inventory, reducing costs, and seeking a bridge loan. Eevia sees commercial opportunities through recent sales contracts but needs capital to realize them. The company aims to reorganize privately, avoiding public restructuring. Audit processes have been delayed due to financial uncertainties, and asset valuations are being conservatively adjusted. Despite these challenges, Eevia remains committed to protecting shareholders and creditors and continues to explore strategic options.

Press release from Companies: Eevia Health Warns of Strained Liquidity and Delayed Audit

för 2 månader sedan

Vitafoods är en viktig mötesplats för nutraceutisk industri, med över 21,500 deltagare från mer än 160 länder. I år hölls evenemanget i Barcelona. Eevia lanserade sin nya produkt FENO-ARONIA™ 50 Organic, en hälsosam ingrediens med hög koncentration av bioaktiva polyfenoler, vilket genererade stort intresse och två snabba beställningar. Eevia ingick också ett långsiktigt avtal om FENO-CHAGA™ Organic med en strategisk partner. Företaget överväger ett råmaterialpartnerskap och fick stöd från styrelseledamoten Dr. Diane Clayton under evenemanget. Eevia Health Plc, grundat 2017, tillverkar organiskt certifierade växtextrakt från finska och svenska skogar. Produkterna säljs globalt som ingredienser till kosttillskott och livsmedelsmärken. Eevia är listat på Spotlight Stock Market i Sverige sedan juni 2021.

Press release from Companies: SUCCESSFUL TRADESHOW AND PRODUCT LAUNCH

för 3 månader sedan

The Corporation, a leader in specialty ingredients for health, beauty, and wellness industries, has entered a new global supply agreement with Eevia after a 20-month collaboration. This partnership, which began with a non-disclosure agreement in October 2023, involved feasibility studies and trials confirming the safety and readiness of Feno-Chaga™ Organic, an extract from Chaga mushrooms. The five-year agreement includes minimum sales volumes and quality standards, with the Partner responsible for marketing and sales. Eevia will focus on manufacturing while the Partner handles clinical research and market expansion. This arrangement allows Eevia to grow revenue and allocate resources to other products. For more details, contact Stein Ulve, CEO of Eevia Health.

Press release from Companies: UPDATE: Eevia Health Enters Five-Year Supply Agreement

för 3 månader sedan

Threads

Föregående

Sida 4

Nästa